Summary
Pfizer Inc. (PFE) filed an 8-K on January 29, 2019, to report its financial results for the fourth quarter and full year ended December 31, 2018. The filing primarily includes a press release announcing these results, which provides investors with key performance indicators and financial highlights for the reporting periods. Investors should review the accompanying press release for detailed information on revenue, earnings, and any forward-looking statements made by the company regarding its financial outlook. The furnished press release is the primary source of information in this 8-K. While the 8-K itself is a notification of the release of these results, the actual substance of the financial performance and any management commentary is contained within the press release. Investors seeking to understand Pfizer's performance in late 2018 and its implications for future strategy and financial health should carefully examine the information presented in Exhibit 99.
Key Highlights
- 1Pfizer Inc. reported its financial results for the fourth quarter and full year 2018 via an 8-K filing on January 29, 2019.
- 2The 8-K filing includes a press release (Exhibit 99) containing the detailed financial results.
- 3Investors can access key performance indicators and financial metrics for Q4 and FY 2018 through the furnished press release.
- 4This filing serves as an official notification of Pfizer's financial performance disclosure.
- 5The information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, but is crucial for investor understanding of recent performance.